Cubist pharmaceuticals stock
WebCubist Pharmaceuticals's latest funding round was a Acquired for on December 8, 2014. Cubist Pharmaceuticals's latest post-money valuation is from December 2014. Sign up for a free trial to see Cubist Pharmaceuticals's valuations in December 2014 and more. WebCubist Pharmaceuticals Inc stock price live 101.94, this page displays NASDAQ CBST stock exchange data. View the CBST premarket stock price ahead of the market session or assess the after hours quote.
Cubist pharmaceuticals stock
Did you know?
WebFind the latest 467037 (CBST) stock quote, history, news and other vital information to help you with your stock trading and investing. WebDec 12, 2011 · Cubist Pharmaceuticals, Inc. today announced that it has completed the previously announced acquisition of Adolor Corporation for an aggregate upfront cash... April 10, 2024
WebJul 14, 2024 · Cubist Pharmaceuticals Inc (NASDAQ:CBST) released its quarterly earnings data on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 … WebApr 6, 2024 · 14 brokers have issued 1 year price objectives for Apellis Pharmaceuticals' shares. Their APLS share price forecasts range from $40.00 to $139.00. On average, they predict the company's share price to reach $78.40 in the next twelve months. This suggests that the stock has a possible downside of 0.5%.
WebStock Price History Stock Splits Market Cap Stock split history for Merck since 1970. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values. Compare MRK With Other Stocks From: To: Zoom: WebMay 10, 2013 · R. K. has received speaking honoraria from Cubist Pharmaceuticals and Forest Laboratories; has served on the advisory board of Optimer Pharmaceuticals; is currently employed by Cubist Pharmaceuticals; and owns Cubist Pharmaceuticals stock. D. A. G. has received grant support from Merck and serves on the advisory board …
WebApr 12, 2024 · Cubist Systematic Strategies LLC now owns 334,168 shares of the biopharmaceutical company’s stock valued at $4,662,000 after buying an additional 261,412 shares during the period. Hedge funds...
WebApr 12, 2024 · Cubist Systematic Strategies LLC now owns 334,168 shares of the biopharmaceutical company’s stock valued at $4,662,000 after purchasing an additional 261,412 shares during the period. t bug apartmentWebMar 15, 2013 · This was an investigator-initiated study funded by Cubist Pharmaceuticals. We acknowledge John Paul McRoberts (Anti-Infective Research Laboratory, Wayne State University) for assistance in the extended microbiological assessment and verification. ... R.K. is now employed by Cubist Pharmaceuticals and owns Cubist Pharmaceuticals … tbug apartment cyberpunkWebCubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA. . The company employed 638 people, mostly in Lexington, MA. … tbug 2022WebApr 10, 2024 · 10 analysts have issued 1 year price objectives for Ionis Pharmaceuticals' stock. Their IONS share price forecasts range from $27.00 to $67.00. On average, they predict the company's share price to reach $45.17 in the next year. This suggests a possible upside of 21.2% from the stock's current price. View analysts price targets for IONS or … t bugWebA. ANTIVENIN™ (LATRODECTUS MACTANS) B. BCG Vaccine (For Percutaneous Use) BELSOMRA® (suvorexant) tablets, for oral use, C-IV. BRIDION® (sugammadex) Injection, for intravenous use. C. CANCIDAS® (caspofungin acetate) for Injection, for intravenous use. CUBICIN® (daptomycin for injection) for Intravenous Use. t-bug apartmentWebSep 5, 2013 · Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced the pricing of $700 million aggregate principal amount of convertible senior unsecured notes that will be issued in two series, with one series of $300 million aggregate principal amount maturing on September 1, 2024 (the 2024 notes) and the other series of $400 million aggregate … tbu gmbhWebPhone Number 7812401261. Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first … t bug cyberpunk